Roth Capital initiated coverage on RenovoRx with a new price target
$RNXT
Biotechnology: Pharmaceutical Preparations
Health Care
Roth Capital initiated coverage of RenovoRx with a rating of Buy and set a new price target of $16.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 11/1/2021 | $16.00 | Buy | Roth Capital |
| 10/6/2021 | $15.00 | Buy | Maxim Group |
8-K - RenovoRx, Inc. (0001574094) (Filer)
SCHEDULE 13G/A - RenovoRx, Inc. (0001574094) (Subject)
10-Q - RenovoRx, Inc. (0001574094) (Filer)
Roth Capital initiated coverage of RenovoRx with a rating of Buy and set a new price target of $16.00
Maxim Group initiated coverage of RenovoRx with a rating of Buy and set a new price target of $15.00
4 - RenovoRx, Inc. (0001574094) (Issuer)
4 - RenovoRx, Inc. (0001574094) (Issuer)
4 - RenovoRx, Inc. (0001574094) (Issuer)
MOUNTAIN VIEW, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced the appointment of renowned UCLA surgeon and pancreatic disease expert Timothy Donahue, MD, to RenovoRx's scientific advisory board (SAB). Dr. Donahue is a nationally recognized expert in pancreatic cancer and serves as the Director of UCLA's Agi Hirshberg Center for Pancreatic Diseases and as Chief of the Division of Surgical Oncology at the David Geffen School of Medicine. He also holds the Garry Shandling Ch
MOUNTAIN VIEW, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life-sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a patented, FDA-cleared drug-delivery device, today announced that Shaun Bagai, Chief Executive Officer, will be participating at the Canaccord Genuity MedTech, Diagnostics & Digital Health & Services Forum, to be held on November 20, 2025. Mr. Bagai will share an update on RenovoRx's commercialization progress, driven by strong clinical need and market demand for RenovoCath as a standalone targeted drug-delivery product among both new and existing customers. He will a
MOUNTAIN VIEW, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that it will host its third quarter 2025 financial results and business highlights conference call on November 13, 2025, at 4:30 p.m. ET. Additional details will be available on the Investor Relations section of the Company's website at https://ir.renovorx.com/. On the call, RenovoRx's management is expected to discuss the latest developments and achievements for its ongoing RenovoCath® device commercialization
4 - RenovoRx, Inc. (0001574094) (Issuer)
4 - RenovoRx, Inc. (0001574094) (Issuer)
4 - RenovoRx, Inc. (0001574094) (Issuer)
MOUNTAIN VIEW, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced the appointment of renowned UCLA surgeon and pancreatic disease expert Timothy Donahue, MD, to RenovoRx's scientific advisory board (SAB). Dr. Donahue is a nationally recognized expert in pancreatic cancer and serves as the Director of UCLA's Agi Hirshberg Center for Pancreatic Diseases and as Chief of the Division of Surgical Oncology at the David Geffen School of Medicine. He also holds the Garry Shandling Ch
LOS ALTOS, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced the appointment of renowned interventional oncologist Thierry de Baère, MD, PhD to RenovoRx's Scientific Advisory Board (SAB). Professor de Baère's expertise is directly relevant to RenovoRx's Trans-Arterial Micro-Perfusion (TAMP™) therapy platform which is enabled by RenovoCath. This patented technology is designed to optimize targeted drug-delivery of therapeutic agents. Professor de Baère is Head of the Interve
LOS ALTOS, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform, announced today that Ryan Witt has joined the Company in the new role as Senior Vice President, Head of Corporate Strategy and Partnerships. Mr. Witt's appointment highlights RenovoRx's commitment to explore and execute on clinical and commercial business development opportunities not only for its RenovoGem™ investigational combination product (currently in Phase III clinical development), but also opportunities with the Company's foundational FDA
SC 13G/A - RenovoRx, Inc. (0001574094) (Subject)
SC 13G - RenovoRx, Inc. (0001574094) (Subject)
SC 13G - RenovoRx, Inc. (0001574094) (Subject)
MOUNTAIN VIEW, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath®, a novel, FDA-cleared drug-delivery device, today announced that it will host its third quarter 2025 financial results and business highlights conference call on November 13, 2025, at 4:30 p.m. ET. Additional details will be available on the Investor Relations section of the Company's website at https://ir.renovorx.com/. On the call, RenovoRx's management is expected to discuss the latest developments and achievements for its ongoing RenovoCath® device commercialization
Equity Insider News Commentary Issued on behalf of GT Biopharma, Inc. VANCOUVER, BC, Oct. 17, 2025 /PRNewswire/ -- Equity Insider News Commentary – MIT and Harvard scientists recently created engineered CAR-NK cells that hide from the immune system and more effectively destroy cancer, opening doors to off-the-shelf treatments doctors can administer immediately after diagnosis instead of waiting weeks for personalized cell production[1]. Eight new oncology approvals between July and September 2025 demonstrate how cellular immunotherapy platforms are solving manufacturing challenges while expanding from blood cancers into solid tumors, with researchers discovering ways to reprogram immune cell
Revenue from RenovoCath® device totaled over $400,000 for the Second Quarter 2025 As of June 30, 2025, the Company had $12.3 million in cash and cash equivalents Management to host conference call today at 4:30 p.m. ET RenovoRx, Inc. ("RenovoRx" or the "Company") (NASDAQ:RNXT), a life sciences company developing innovative targeted oncology therapies and commercializing RenovoCath, a novel, FDA-cleared drug-delivery device, today announced its financial results and business update to shareholders for the second quarter ended June 30, 2025. "We are pleased to report second quarter 2025 revenue of over $400,000. This growth highlights the strong clinical need and market demand for our